Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
Adjuvant Post-Tamoxifen Exemestane Trial
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2008-12-18
- Lead Sponsor
- Hellenic Breast Surgeons Society
- Target Recruit Count
- 448
- Registration Number
- NCT00810706
- Locations
- 🇬🇷
Hellenic Breast Surgeons Society, Athens, Greece
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT00810797
- Locations
- 🇺🇸
South Pasadena Cancer Center, South Pasadena, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2012-11-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00793546
- Locations
Pfizer Investigational Site
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 93
- Registration Number
- NCT00728949
- Locations
- 🇺🇸
ImClone Investigational Site, Nashville, Tennessee, United States
Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 109
- Registration Number
- NCT00719966
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2009-06-17
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 70
- Registration Number
- NCT00687648
- Locations
- 🇸🇬
National Cancer Centre - Singapore, Singapore, Singapore
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Gruppo Italiano Mammella (GIM)
- Target Recruit Count
- 396
- Registration Number
- NCT00688194
- Locations
- 🇮🇹
Federico II University Medical School, Naples, Italy
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT00676663
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Memorial Cancer Institute, Hollywood, Florida, United States
Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer
- Conditions
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 111
- Registration Number
- NCT00674557
- Locations
- 🇬🇧
Cancer Research UK Medical Oncology Unit at Churchill Hospital & Weatherall Institute of Molecular Medicine - Oxford, Oxford, England, United Kingdom
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
- Conditions
- Interventions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 86
- Registration Number
- NCT00659373
- Locations
- 🇺🇸
Front Range Cancer Specialists, Fort Collins, Colorado, United States
🇺🇸New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care, Concord, New Hampshire, United States
🇺🇸Batte Cancer Center at Northeast Medical Center, Concord, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.